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Cancer-Related Chronic Pain
Examining Quality of Life in Diverse Cancer Survivors
Carmen R. Green, MD1,2,3; Tamera Hart-Johnson, MS1; and Deena R. Loeffler, MA1
BACKGROUND: Disparities in cancer survival and pain rates negatively impact quality of life (QOL). This study examines
cancer-related chronic pain (CP) and its impact on QOL in diverse cancer survivors. METHODS: This survey study focused
on current and past pain, health, and QOL in black and white cancer survivors. Participants with breast, colorectal, lung,
and prostate cancer and multiple myeloma were recruited through the Michigan State Cancer Registry. Analysis of var-
iance was used to examine outcome differences by pain status, race, and sex. Hierarchical regressions explored predictors
for experiencing pain. RESULTS: The subjects (N ¼ 199) were 31% black, 49% female, and 57 to 79 years old; 19.5% experi-
enced current pain, and 42.6% reported pain since diagnosis.Women experience more pain (P < .001) and greater pain se-
verity (P ¼ .04) than men. Blacks experienced more pain interference and disability (P < .05). Experiencing pain is related
to greater depressive symptoms, poorer functioning, and more symptoms. In hierarchical regressions, female sex
predicted pain since diagnosis; pain severity for pain since diagnosis was predicted by black race and female sex.
CONCLUSIONS: The authors extend the literature by showing that 20% of diverse cancer survivors had cancer-related CP,
and 43% had experienced pain since diagnosis, revealing racial and sex disparities in cancer-related CP’s incidence and
impact on QOL. Having pain was related to poorer QOL in several domains and was more frequently experienced by women.
Although black race was not related to pain prevalence, it was related to greater severity. This study reveals an unaddressed
cancer survivorship research, clinical, and policy issue. Cancer 2011;117:1994–2003.VC 2010 American Cancer Society.
KEYWORDS: cancer, pain, quality of life, health, survivorship, sex, race and ethnicity, disparities, cancer-related
chronic pain.
Chronic pain, the third largest global public health problem, remains a neglected topic in medicine.1-5 Pain com-
plaints and cancer are increasing as more people survive cancer and chronic diseases.5,6 In the US, pain is the most frequent
cause of disability and second leading cause for physician visits, and is associated with depression, anxiety, and sleep dis-
turbance.7,8 The National Cancer Institute (NCI) estimates most (>60%) people diagnosed with cancer will be alive in 5
years.9 According to the Lance Armstrong Foundation and NCI, survivorship begins at diagnosis; however, pain threatens
health and quality of life (QOL).10 Most (60%-85%) people with advanced cancer and nearly 40% of 5-year survivors
report pain.1,11-13 Many unscheduled hospital admissions (14%-26%) are because of uncontrolled pain, costing >$10
million in expenditures.14 However, cancer-related chronic pain (CP) remains a poorly explored survivorship issue, espe-
cially among diverse cancer survivors.6,15-18 As America ages and diversifies the increasing prevalence of cancer, pain, and
cancer-related CP will have significant individual and societal ramifications.19
Increased longevity and QOL have not been uniformly translated.20 Minorities are more likely to report diminished
health, less likely to have a physician, have less access to specialists, and experience increased disease burden, even when
their health insurance and socioeconomic status are similar to whites.1,21-25 Cancer remains the second leading cause of
death in the United States, and significant disparities exist.18,24,26 Despite increased awareness, a knowledge gap exists
regarding cancer-related CP in diverse cancer survivors.
The literature documents the benefits of optimizing pain management, but disturbing variability and disparities based
on sociodemographic characteristics remain.1-4,12,18 Bernabei revealed black nursing home residents with cancer pain were
63% more likely than whites to receive no pain medications.27 Sex-based differences in pain care are known, with women
referred to pain specialists less frequently than men.2-4 Also, structural barriers prevent minorities from being able to fill their
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prescriptions in their local pharmacies.28,29 Critically im-
portant data to ensure appropriate pain and healthcare
planning are lacking, yielding a significant literature gap.18
Despite the importance of cancer, pain, and health
disparities, it is unknown whether the increased health per-
turbations seen with CP aremore pronounced in cancer sur-
vivors. This study in black and white survivors hypothesizes
that the prevalence, etiology, characteristics, and sequelae
(eg, QOL) of cancer-related CP vary by race and sex. This
study was designed to 1) identify and compare the relative
prevalence, etiology, and characteristics of cancer-related
CP; 2) investigate and compare the relationship between
cancer-related CP and mental health, disability, and QOL;
and 3) evaluate and compare sociodemographics, attitudes,
and pain care factors influencing cancer-related CP poten-
tially mediating the relations described above.
MATERIALS AND METHODS
Participants
The University of Michigan Health System Institutional
Review Board and the Michigan State Cancer Registry
Institutional Review Board granted study approval. Each
participant provided written informed consent upon
enrollment. Adult survivors (18-90 years old) who experi-
enced breast, prostate, colorectal, or lung cancer or multi-
ple myeloma with initial diagnosis at least 2 years prior
provided study data. Survivor was defined in accordance
with the Lance Armstrong Foundation and NCI, which
define survival from the moment of diagnosis. Because of
geographic reporting inconsistencies, we used diagnosis
plus 2 years to ensure consistency.10
The Michigan State Cancer Registry stratified their
database by race and randomly identified black and non-
Hispanic white potential subjects, cross-checked death
records, verified addresses, and contacted physicians to
ensure there were not contraindications to participation.
Up to 3 letters were mailed, the last certified, with an in-
terest form and return envelope. Information from partic-
ipants returning signed interest forms was forwarded from
Michigan State Cancer Registry to the study team. The
research office then mailed participants’ information and
the survey using Dillman’s Total Design Method.30 A
modest $20 incentive was sent on receipt of the survey.
Measures
Sociodemographics included age, self-identified race, sex,
marital status, education, employment, and household
income.
Cancer and treatment information was self-reported
and confirmed through registry report. Cancer informa-
tion included diagnosis, date, stage, and current status
(cancer-free, remission, active and receiving treatment,
active and not receiving treatment). A treatment checklist
was included: chemotherapy, radiation therapy, hormone
therapy, and surgery. Participants could check all that
applied and marked when they had last received each
treatment (never, 0-3 months ago, 3-12 months ago, 1-2
years ago,>2 years ago, do not recall).
Current pain was used to establish skip patterns in
the survey, with the question, ‘‘Do you currently experi-
ence pain regularly?’’ Participants were asked to classify
pain: consistent pain, consistent pain that sometimes had
much stronger pain flares, pain flares only, or pain only
related to certain activities or motions. The same screening
questions were again asked related to pain since cancer.
The Brief Pain Inventory (BPI) assessed pain sever-
ity and interference with normal functioning.31 Items
determined pain severity (at worst, least, average, and
right now), pain-related interference (eg, mood, work,
relationships, sleep), pain characteristics (eg, timing, dura-
tion, quality), pain location (via 2 drawings of the body),
pain duration and description (ie, consistent, flares, or
both), pain-related medications and percentage of pain
relieved by medication, and an open-ended item regard-
ing what actions relieved pain. A subset of questions was
repeated for past pain, in addition to documenting the
timing of cancer pain when the participant was no longer
experiencing pain.
The Center for Epidemiological Studies Depression
Scale assessed depressed affect. We dropped the 4 posi-
tively worded items from the original 20-item survey,
because factor analysis showed the items do not accurately
predict negative affect when reversed, as confirmed in the
literature for cancer patients.32 Responses for the remain-
ing 16 items were summed and weighted to calculate an
overall score comparable to the published scale range
(0-60; scores >15 indicated severe psychological distress
and depression). Internal consistency was consistent with
published values (a¼ .91).32
The John Henryism Active Coping Scale evaluated
a high output active coping strategy characterized by pro-
tracted struggles against seemingly insurmountable
obstacles. Originally reported in older blacks, it is corre-
lated with high blood pressure and bodily pain. The sum
score of 12 Likert-type items was calculated (60 ¼ maxi-
mum active coping score). Internal consistency (a ¼ .87)
was higher than published values.33
Pain and QOL in Diverse Cancer Survivors/Green et al
Cancer May 1, 2011 1995
The Barriers Questionnaire assessed attitudes to-
ward pain management and has 4 separate subscales:
physiological effects, fatalism, communication, and harm-
ful effects.34 Mean scores were calculated for each set sub-
scale; fatalism items were reverse scored before analysis.
The internal consistency for subscales ranged from a ¼
.60 to a¼ .91. Only the fatalism subscale had a reliability
value below published values of a¼ .79.34 Reliability was
a ¼ .60. It is possible that our small sample size, the few
questions on the subscale, and potential differences in the
meaning to survivors may account for this difference.
The Pain Disability Index (PDI) evaluated the
impact of CP on the individual via summation of seven
11-point subscales representing 7 life domains (family,
occupation, recreation, social, sexual, life-support, and
self-care) and the amount of impairment (0 ¼ no disabil-
ity, 10 ¼ total disability, 70 ¼ maximum disability).35
PDI was weighted, allowing for up to 2 missing items.
The European Organisation for the Research and
Treatment of Cancer survey assessed health-related quality
of life.36 Five QOL functioning domains (eg, cognitive,
emotional, physical) and 8 symptom-control domains (eg,
anorexia, dyspnea, fatigue) were evaluated for their contri-
bution to QOL. Additional measures assessed financial
concerns, global health, and overall QOL. Scores were line-
arly transformed to a 0 to 100 scale. Internal consistency of
the subscales (a¼ .71-.91) was high.36
Statistical Analysis
Descriptive statistics were calculated using PSAW 18.0.
Analysis of variance and chi-square analysis were used for
group comparisons; because of multiple comparisons; a
conservative P ¼ .01 was used to determine significance.
Hierarchical logistic regression examined predictors of
current pain and pain at any time since cancer diagnosis.
Age and dummies for black race and female sex were
entered at Block 1, income and education at Block 2.
Prostate cancer, related to lower pain rates than other can-
cers, was used for cancer type; chemotherapy was related
to current and any pain; radiation and hormone treat-
ments were predictive of having had pain since diagnosis;
likewise, cancer surgery was listed as the most common
pain cause, so dummy variables were used for each treat-
ment. All were added in the final block, followed by mul-
tivariate regression among those who had experienced
pain (using the same prediction variables, to test for pre-
dictors of pain severity). Because of the smaller sample
size and lack of relationship with pain severity, radiation,




Nine hundred fifty participants were identified in the 2
waves (450 whites, 500 blacks). Blacks were more likely to
be deceased (n ¼ 70 vs n ¼ 33), have physicians express-
ing contraindication (n ¼ 45 vs n ¼ 32), and have bad
addresses (n ¼ 71 vs n ¼ 28); leaving 670 people (49%
female, 47% black) eligible to contact. Blacks were less
likely to actively refuse participation (n ¼ 44 vs n ¼ 86;
19.4% overall), but were also less likely to actively agree in
addition to the greater mortality and mobility, so were less
likely to be forwarded to the research office (n ¼ 105
black [33.5%]; 158 white [44.3%]; 39.3% overall) and
represented a smaller percentage to complete surveys (n¼
61 black [19.5%]; 137 white [38.4%]). Respondents
(N ¼ 199) were 31% black, 49% female, and from 42 to
87 years old. One person reported their race as Arabic/East
Asian and was not included in racial comparisons. Most
participants were currently cancer free or in remission
(95.2% women, 95.7% men, 94.3% blacks, 98.2%
whites). Cancer type differed by sex (P < .001) but not by
race. Blacks tended to have lower incomes (P¼ .04), lower
cancer stages, and lower surgery rates. Women had higher
rates of chemotherapy, radiation, and hormone therapy
and were more likely to lack insurance (P ¼ .02). Table 1
provides information about the sample’s characteristics.
Most (>90%) of ‘‘most recent’’ treatments were received
>1 year prior. Other than hormone treatment, >85% of
the other treatments had occurred>2 years earlier.
Group Differences
Nearly 20% (19.5%) experienced current pain. Women
experienced more pain since diagnosis than men (56% vs
30%; P < .001). Tables 2 and 3 provide data on cancer
and pain characteristics by group. Pain flares were the most
common pain form and were more common in women than
men (P ¼ .03). Twice as many women reported more pain
with activities than men (50% vs 24%; P ¼ .05). The most
significant source of pain was cancer surgery (53.8%) for
whites and cancer treatment (46.2%) for blacks. Blacks with
pain reported higher pain severity for pain since diagnosis
(P ¼ .001). Women experienced more pain since diagnosis
(P < .001). Although not all results are significant, many
findings trended the same direction, with blacks and
women faring worse. Blacks experienced more interfer-
ence from pain (mood and walking ability) and greater
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Age, y 68.1  10.5 67.2  10.6 68.1  10.6 F ¼ 0.21 71.6  7.8 64.0  11.6 F ¼ 29.8 (<.001)a
% black 31% — — 31.6% 29.6% v2 ¼ 1.11 (.57)
% women 49% 47.5% 49.6% v2 ¼ 1.11 (.57) — —
Education v2 ¼ 11.0 (.53) v2 ¼ 7.68 (.26)
£6th grade 6.4% 7.0% 6.1% 8.2% 4.4%
7th-<12th 3.2% 5.3% 2.3% 5.2% 1.1%
High school 26.2% 19.3% 29.0% 27.8% 24.4%
Some college 31.0% 40.4% 26.7% 29.9% 32.2%
College graduate 23.0% 22.8% 22.9% 17.5% 28.9%
Graduate school 10.2% 5.3% 13.0% 11.3% 8.9%
Income, $ v2 ¼ 24.6 (.04) v2 ¼ 5.54 (.60)
£9,999 1.7% 3.8% 0.8% 2.2% 1.1%
10,000-20,000 15.0% 28.3% 9.4% 12.1% 18.2%
20,001-40,000 26.1% 15.1% 31.5% 26.4% 26.1%
40,001-60,000 19.4% 24.5% 16.5% 23.1% 9.6%
60,001-100,000 23.3% 18.9% 26.0% 23.1% 23.9%
‡100,001 13.9% 9.4% 15.7% 13.2% 14.8%
No insurance 3.2% 3.1% 3.5% v2 ¼ 0.50 (.97) 0% 6.7% v2 ¼ 7.75 (.02)
Cancer type v2 ¼ 4.56 (.92) v2 ¼ 162.9 (<.001)a
Breast 40.4% 35.1% 43.2% 2.1% 81.3%
Colorectal 9.6% 10.5% 9.1% 6.2% 13.2%
Lung 4.8% 5.3% 4.5% 5.2% 4.4%
Multiple myeloma 1.6% 3.5% 0.8% 3.1% 0.0%
Prostate 41.0% 43.9% 39.4% 79.4% 0.0%
Other 2.7% 1.8% 3.0% 4.1% 1.1%
Cancer stage (at worst) v2 ¼ 28.4 (.01)a v2 ¼ 8.55 (.29)
I 21.9% 30.8% 19.5% 18.6% 25.6%
II 14.4% 13.5% 17.2% 10.3% 18.9%
III 7.0% 5.8% 7.8% 8.2% 5.6%
IV 5.3% 1.9% 6.3% 5.2% 5.6%
Unknown 51.3% 48.1% 48.1% 57.7% 55.6%
Treatments received
Chemotherapy 36.2% 42.6% 33.9% v2 ¼ 2.95 (.23) 17.2% 57.1% v2 ¼ 30.5 (<.001)a
Radiation 50.9% 50.0% 51.2% v2 ¼ 0.02 (.88) 40.7% 61.9% v2 ¼ 7.89 (.005)a
Hormone therapy 11.4% 7.0% 14.0% v2 ¼ 1.97 (.37) 5.2% 18.0% v2 ¼ 7.48 (.006)a
Surgery 73.5% 58.9% 79.2% v2 ¼ 8.60 (.01)a 68.8% 78.8% v2 ¼ 2.33 (.13)
a Statistically significant.
Table 2. Pain Prevalence and Severity by Cancer Type and Stage
Percentage
With Current










Breast, n 5 84 25.0% 2.47  1.71 58.3% 3.49  1.93
Colorectal, n 5 17 23.5% 2.06  1.46 41.2% 4.00  2.10
Lung, n 5 9 22.2% 4.00  1.77 55.6% 2.92  2.04
Multiple myeloma, n 5 3 33.3% 0.00a 100.0% 7.44  2.14b
Prostate, n 5 81 14.8% 1.34  1.07 28.4% 4.57  1.95
Cancer stage at worst
I, n 5 49 24.5% 2.38  2.15 53.1% 4.24  2.14
II, n 5 35 20.0% 2.39  1.17 57.1% 2.94  1.24
III, n 5 14 25.6% 2.35  1.96 50.0% 4.92  3.77
IV, n 5 5 20.0% 1.25a 60.0% 5.67  0.94
Unknown, n 5 79 16.5% 1.74  1.35 32.9% 4.08  2.48
a n ¼ 1 in cell, there is no standard deviation.
bMultiple myeloma has a significantly higher past pain level than all others.















Currently experience pain 20.1% 21.3% 19.7% v2 ¼ 0.32 (.845) 16.8% 23.5% v2 ¼ 1.37 (.24)
Experienced pain since cancer 44.2% 39.3% 46.7% v2 ¼ 1.73 (.42) 31.7% 57.1% v2 ¼ 13.07 (<.001)a
Kind of pain (those experiencing
current pain)b
n¼40 n¼13 n¼27 n¼17 n¼23
Chronic consistent 11.3% 15.8% 9.6% v2 ¼ 0.53 (.47) 21.7% 6.4% v2 ¼ 0.27 (.60)
Acute consistent 14.1% 10.5% 15.4% v2 ¼ 0.27 (.60) 17.4% 12.8% v2 ¼ 0.09 (.77)
Consistent 1 flares 11.3% 15.8% 9.6% v2 ¼ 0.53 (.47) 13.0% 10.6% v2 ¼ 0.94 (.33)
Flares only 43.8% 42.1% 44.4% v2 ¼ 0.03 (.86) 34.8% 46.9% v2 ¼ 4.59 (.03)
Pain with activities 41.9% 31.5% 45.5% v2 ¼ 1.12 (.29) 24.0% 50.0% v2 ¼ 5.82 (.05)
Number of pain locations 1.63  2.21 0.60  1.26 2.78  2.54 F ¼ 5.79 (.03) 0.75  1.75 2.27  2.37 F ¼ 2.25 (.14)
Pain cause (multiple responses permitted)c
Cancer 14.6% 30.8% 7.1% v2 ¼ 3.97 (.05) 12.5% 16.0% v2 ¼ 0.10 (.76)
Cancer treatment 32.5% 33.3% 32.1% v2 ¼ 0.01 (.94) 25.0% 37.5% v2 ¼ 0.68 (.41)
Cancer surgery 35.0% 25.0% 39.3% v2 ¼ 0.75 (.39) 31.3% 37.5% v2 ¼ 0.17 (.69)
Accident/injury 21.4% 15.4% 24.1% v2 ¼ 0.41 (.52) 33.3% 12.5% v2 ¼ 2.65 (.10)
Illness/disorder 39.0% 30.8% 42.9% v2 ¼ 0.83 (.36) 58.8% 25.0% v2 ¼ 4.78 (.03)
Percentage of pain relieved with
medication (100¼full relief)c
61.19% 71.1% 55.4% F ¼ 1.64 (.21) 62.6% 60.1% F ¼ 0.40 (.84)
BPI pain severity, current painc 2.07  1.61 2.21  2.06 2.00  1.33 F ¼ 0.17 (.69) 1.51  1.39 2.54  1.65 F ¼ 4.68 (.04)
BPI pain interferencec
General activity 2.76  2.74 2.86  3.25 2.71  2.51 F ¼ 0.25 (.88) 2.33  2.68 3.08  2.80 F ¼ 0.77 (.39)
Mood 2.79  2.89 4.00  3.09 2.04  2.54 F ¼ 4.63 (.04) 2.33  2.89 3.19  2.91 F ¼ 0.85 (.36)
Walking ability 3.48  3.41 4.93  3.65 2.67  3.04 F ¼ 4.64 (.04) 4.21  3.58 2.87  3.21 F ¼ 1.64 (.21)
Work 3.76  3.24 5.00  3.82 3.04  2.68 F ¼ 3.73 (.06) 3.83  3.52 3.70  3.08 F ¼ 0.02 (.90)
Relationships 2.32  3.13 2.73  3.37 2.08  3.03 F ¼ 0.41 (.53) 2.67  3.41 2.04  2.95 F ¼ 0.39 (.53)
Sleep 3.44  3.13 4.40  3.11 2.93  3.07 F ¼ 2.23 (.14) 3.63  3.42 3.29  2.94 F ¼ 0.12 (.73)
Enjoyment of life 3.09  3.29 4.07  3.77 2.57  2.94 F ¼ 2.06 (.16) 2.84  3.39 3.29  3.28 F ¼ 0.19 (.66)
BPI severity, pain since cancer 3.94  2.12 5.35  1.87 3.35  1.96 F ¼ 13.18 (.001)a 5.03  2.06 3.44  1.97 F ¼ 8.13 (.006)a
Attitudes about pain treatment
Fatalism 2.30  0.92 2.58  0.97 2.18  0.87 F ¼ 7.32 (.008)a 2.28  0.91 2.33  0.93 F ¼ 0.11 (.74)
Physical barriers 2.76  0.82 2.80  0.92 2.75  0.78 F ¼ 0.15 (.70) 2.88  0.80 2.67  0.84 F ¼ 2.90 (.09)
Communication barriers 1.96  0.84 1.89  0.82 1.99  0.85 F ¼ 0.48 (.49) 1.97  0.78 1.97  0.90 F ¼ 0.00 (.97)
Harmful effects 2.94  1.03 3.18  1.17 2.83  0.94 F ¼ 4.19 (.04) 3.11  0.99 2.82  1.05 F ¼ 3.44 (.07)
Pain Disability Index
Family 3.65  3.42 5.50  3.70 2.76  2.95 F ¼ 6.91 (.01)a 3.56  3.38 3.72  3.52 F ¼ 0.02 (.88)
Recreation 4.23  3.35 5.80  3.59 3.41  2.96 F ¼ 5.56 (.02) 4.79  3.29 3.80  3.39 F ¼ 0.94 (.34)
Social activity 3.02  3.41 4.00  3.91 2.52  3.08 F ¼ 1.91 (.18) 3.74  3.54 2.48  3.28 F ¼ 1.48 (.23)
Occupation 3.49  3.87 5.21  4.40 2.66  3.35 F ¼ 4.47 (.04) 3.26  3.89 3.67  3.93 F ¼ 0.11 (.74)
Sexual behavior 4.77  4.40 5.93  4.28 4.14  4.41 F ¼ 1.64 (.21) 5.79  4.44 3.96  4.29 F ¼ 1.87 (.18)
Self-care 1.82  3.28 4.33  4.45 0.52  1.21 F ¼ 19.0 (<.001)a 1.63  3.34 1.96  3.30 F ¼ 0.11 (.75)
Life support 1.73  2.80 3.47  3.56 0.83  1.79 F ¼ 10.8 (.002)a 2.05  3.17 1.48  2.52 F ¼ 0.45 (.51)
Depression 10.5  9.2 11.5  10.6 9.8  8.4 F ¼ 1.47 (.23) 8.6  7.2 12.4  10.6 F ¼ 7.78 (.006)a
Functioning
General health 78.3  17.4 73.8  19.8 80.2  16.0 F ¼ 5.25 (.02) 79.6  16.2 76.7  18.8 F ¼ 1.26 (.26)
Physical 82.9  20.9 75.8  25.7 86.0  17.6 F ¼ 9.70 (.002)a 85.0  20.6 80.2  21.0 F ¼ 2.50 (.12)
Role 86.5  24.9 83.3  31.8 87.9  21.2 F ¼ 1.33 (.25) 89.2  21.9 83.2  27.6 F ¼ 2.76 (.10)
Emotional 79.5  20.9 78.1  23.1 80.0  19.9 F ¼ 0.33 (.57) 81.8  18.9 76.6  22.5 F ¼ 3.01 (.08)
Cognitive 82.8  24.5 80.7  25.7 83.7  24.0 F ¼ 0.60 (.44) 86.1  18.7 78.8  29.1 F ¼ 4.28 (.04)
Social 87.3  23.3 81.3  31.5 89.8  18.3 F ¼ 5.43 (.02) 87.0  22.7 87.0  24.2 F ¼ 0.00 (1.0)
Symptoms
Fatigue 24.2  24.8 27.4  30.2 22.8  22.1 F ¼ 1.28 (.26) 21.1  24.1 28.2  25.2 F ¼ 3.83 (.05)
Nausea/vomiting 5.2  17.0 8.4  18.9 3.8  15.9 F ¼ 3.11 (.08) 4.1  12.7 6.8  20.8 F ¼ 1.16 (.28)
Pain 19.5  25.5 20.3  29.0 19.2  24.1 F ¼ 0.07 (.79) 16.8  23.4 23.0  27.4 F ¼ 2.68 (.10)
Trouble sleeping 26.0  31.3 27.9  36.7 25.3  28.9 F ¼ 0.27 (.60) 24.7  30.5 28.1  32.5 F ¼ 0.52 (.47)
Appetite 8.3  19.91 13.5  24.3 6.1  17.4 F ¼ 5.60 (.02) 6.2  15.5 11.0  23.9 F ¼ 2.72 (.10)
Shortness of breath 16.2  26.1 19.3  28.1 14.9  25.2 F ¼ 1.13 (.29) 14.1  23.0 19.0  29.0 F ¼ 1.69 (.19)
Constipation 14.7  27.4 24.6  32.4 10.4  23.8 F ¼ 11.1 (.001)a 14.1  25.4 15.9  29.7 F ¼ 0.21 (.65)
Diarrhea 8.2  20.2 11.7  24.8 6.6  17.7 F ¼ 2.53 (.11) 6.5  15.7 15.0  27.5 F ¼ 1.67 (.20)
Financial difficulty 13.8  28.2 21.4  35.1 10.6  24.1 F ¼ 5.95 (.02) 9.7  21.6 18.7  33.4 F ¼ 4.79 (.03)
BPI indicates Brief Pain Inventory.
a Statistically significant.
b Chronic, >3 months; acute, <3 months; consistent means steady pain; flares are pain that varies greatly in strength, coming and going.
cQuestion were asked only of those with current cancer-related pain.
pain-related disability in several PDI domains, expressed
more fatalism and concerns about harmful pain treat-
ment effects, had poorer general health (P ¼ .02) and
physical (P ¼ .002) and social (P ¼ .02) functioning,
had greater appetite symptoms (P ¼ .02), and had more
constipation (P ¼ .001) than whites. Women reported
poorer cognitive functioning than men (P ¼ .04) and
more depressive symptoms (P ¼ .006). Both blacks and
women reported more financial difficulties (P < .05).
Additional comparisons are in Table 3.
Pain Versus No Pain
Participants with current pain reported poorer general
health (P ¼ .001) and physical (P < .001), role (P <
.001), and social (P < .001) functioning. Pain since diag-
nosis predicts all European Organisation for the Research
and Treatment of Cancer survey functioning scales (P <
.01), 3 symptom scales (P < .01), and depression (P ¼
.01). Participants with past pain also reported significantly
greater financial difficulty (P¼ .003). Participants experi-
encing pain since diagnosis endorsed pain medications’
harmful effects less than those who had not experienced
pain (P¼ .01). Table 4 and Figures 1 and 2 provide addi-
tional details.
Predicting Pain
Logistic regression examined predictors for current pain
and pain at any time since cancer diagnosis. Age, race, and
female sex were entered at Block 1, income and education
at Block 2. Prostate cancer, chemotherapy, radiation, hor-
mone therapy, and cancer surgery were added in the final
block.When logistic regression was run, there were no sig-
nificant predictors for current pain. Female sex predicted
having had pain since the time of cancer diagnosis at block
of entry. There were no significant predictors in the final
model. Table 5 shows odds ratios, intervals, and signifi-
cance for variables in all regressions.
Among participants with pain in multiple regres-
sion, there were no significant predictors for current pain
severity as measured by BPI, but pain since diagnosis was
significantly related to female sex (b¼ -.43, P¼ .02) and
black race (b¼ .45, P< .001).
DISCUSSION
There are few racial differences in the prevalence of cancer
by race, but stark racial disparities in morbidity and mor-
tality.37 To our knowledge, this is the first study showing
that nearly 20% of black and white cancer survivors (> 2

















Fatalism 2.51  0.97 2.26  0.89 F ¼ 2.21 (.14) 2.28  0.96 2.33  0.88 F ¼ 0.11 (.74)
Physical barriers 2.87  0.78 2.74  0.83 F ¼ 0.73 (.40) 2.71  0.80 2.81  0.84 F ¼ 0.66 (.42)
Communication barriers 2.05  0.85 1.94  0.84 F ¼ 0.50 (.48) 1.92  0.84 1.99  0.85 F ¼ 0.22 (.64)
Harmful effects 3.06  1.03 2.93  1.03 F ¼ 0.47 (.49) 2.74  0.98 3.12  1.04 F ¼ 6.11 (.01)a
Depression 13.8  11.1 9.6  8.5 F ¼ 6.12 (.02) 12.4  11.0 8.9  7.3 F ¼ 6.63 (.01)a
Functioning
General health 69.7  18.8 80.3  16.4 F ¼ 11.6 (.001)a 74.4  18.7 80.9  15.9 F ¼ 6.50 (.01)a
Physical 68.5  26.5 86.4  17.4 F ¼ 25.1 (<.001)a 77.0  25.1 87.4  15.4 F ¼ 12.02 (.001)a
Role 68.0  35.0 90.9  19.3 F ¼ 29.1 (<.001)a 77.6  31.3 93.0  15.9 F ¼ 19.9 (<.001)a
Emotional 74.1  23.6 80.8  20.0 F ¼ 3.05 (.08) 74.2  23.1 83.4  18.1 F ¼ 9.51 (.002)a
Cognitive 77.0  26.2 84.1  23.8 F ¼ 2.52 (.11) 76.5  29.3 87.3  18.8 F ¼ 9.46 (.002)a
Social 90.3  20.1 90.3  20.1 F ¼ 15.3 (<.001)a 81.0  26.4 91.7  19.6 F ¼ 10.26 (.002)a
Symptoms
Fatigue 45.4  29.7 19.1  20.5 F ¼ 38.5 (<.001)a 35.6  27.2 15.7  18.7 F ¼ 34.5 (<.001)a
Nausea/vomiting 5.6  13.0 5.2  17.9 F ¼ 0.02 (.90) 3.4  9.7 6.7  20.8 F ¼ 1.79 (.18)
Pain 45.4  31.3 13.6  19.5 F ¼ 59.6 (<.001)a 30.2  28.9 11.9  19.2 F ¼ 27.2 (<.001)a
Trouble sleeping 41.7  38.5 22.9  28.5 F ¼ 11.0 (.001)a 36.3  33.2 19.3  28.1 F ¼ 14.5 (<.001)a
Appetite 16.2  25.6 6.5  17.9 F ¼ 7.34 (.007)a 12.3  22.6 5.5  17.2 F ¼ 5.71 (.02)
Shortness of breath 25.2  32.8 14.1  23.7 F ¼ 5.62 (.02) 20.2  29.2 13.3  23.1 F ¼ 3.26 (.07)
Constipation 25.2  31.8 12.2  25.6 F ¼ 6.99 (.009)a 18.8  29.0 11.8  25.8 F ¼ 3.02 (.08)
Diarrhea 11.7  19.6 7.4  20.3 F ¼ 1.36 (.25) 7.9  17.0 8.5  22.3 F ¼ 0.04 (.85)
Financial difficulty 24.1  37.9 11.5  24.8 F ¼ 6.03 (.02) 20.8  34.1 8.8  21.5 F ¼ 8.88 (.003)
a Statistically significant.
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years from diagnosis) report current chronic pain, and
44% have experienced pain since their diagnosis, compa-
rable to previous studies.38,39 We identified differences in
pain type, number of pain locations, perceived etiology,
pain severity, pain interference, disability, functioning,
and symptoms, with blacks and women adversely
impacted. Although blacks tended to have a lower cancer
stage than whites, consistent with physician variability in
decision making, we identified differences in cancer treat-
ment with women more likely to have chemotherapy and
blacks having lower surgery rates.40 Although the cross-
sectional design cannot determine causality, our results
suggest that pain associated with cancer may cause
increased morbidity and diminished QOL for blacks and
women, consistent with an unequal burden of cancer,
pain, and cancer-related CP.24 As more people survive
cancer and develop chronic pain (especially cancer-related
CP), these cross-cutting findings address a significant
knowledge gap and survivorship issue, while highlighting
significant clinical and health policy issues.
The literature reveals a significant financial toll asso-
ciated with cancer. We found blacks and women reported
more financial difficulties than their counterparts, with
women less likely to have insurance. Blacks and women
with chronic pain report increased difficulty paying for
healthcare and are more likely to believe sex, race, ethnicity,
and culture influence access to health and pain care.25,29
Thus, sex and race are important considerations in ensuring
access to quality health and pain care.28,41 Although we did
not show a difference in the prevalence of pain or depres-
sion, other investigators revealed increased pain severity
and impairment for blacks.15,16,42,43 However, when blacks
experienced cancer-related CP, they had increased pain
severity, depression, and disability compared with whites
(P < .05).18,25 Women had increased pain, more pain
flares, more disability because of pain, and were more
depressed than men (P< .05). Because depression is often
poorly assessed and frequently goes without treatment,
they may suffer substantially more impairment in their
health and QOL.
Despite significant medical advances, multimodal
pain therapies, and improved longevity, most cancer sur-
vivors reporting pain reported that their pain was only
relieved by 61%. There are opportunities to improve the
Figure 2. Current functioning and symptoms by experience
of current pain among cancer survivors are shown according
to the European Organisation for the Research and Treat-
ment of Cancer survey. Current pain was related to a greater
number of symptom scales, but only 4 of the 6 functioning
scales.
Figure 1. Current functioning and symptoms by experience of
pain since diagnosis among cancer survivors are shown
according to the European Organisation for the Research and
Treatment of Cancer survey. All functioning and 4 symptom
outcomes were significantly poorer for participants who had
experienced pain.
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quality of clinical care for survivors. When necessary and
appropriate, both pharmacologic and nonpharmacologic
therapies such as counseling should be incorporated to
optimize pain care and improve QOL. However, patient
and physician knowledge and attitudes about pain man-
agement (eg, opioids and nonpharmacological modalities)
may contribute to suboptimal care. For instance, concerns
about side effects (eg, addiction) may affect communica-
tion and coping and lead both to minimize pain com-
plaints.3,4,44 Differences in communication styles may
compromise a patient’s willingness to disclose concerns
and the physician’s willingness to address concerns.45 For
blacks and women, differences in communication styles
may hamper physician decision making, but are critical
for quality pain care. Future studies should design inter-
ventions to optimize physician patient communication,
address attitudes regarding pain management, and
decrease physician variability in decision making to
improve the quality of pain care.
Having current or past pain significantly impaired
health. Participants with pain reported more symptoms
(including depression), decreased QOL, and increased finan-
cial difficulties. Having cancer-related CP decreased all QOL
domains, with an increased health and financial burden for
blacks and women. Surprisingly, there were no predictors for
current pain in our final model. Pain since diagnosis was sig-
nificantly related to black race and female sex. Although our
findings suggest disparities based upon social determinants,
future cancer-related CP studies should attempt to disentan-
gle their role using larger diverse samples.
Despite our important findings, we acknowledge
limitations. First, although the surveys had no identifiers,
were collected in a confidential manner, and were chosen
to determine global differences, there is potential for a
self-report bias. Second, a representation bias could be
present, with people in better health more willing and
able to participate, and it is possible that these estimates
may understate the percentage of survivors experiencing






















0.025/.41 0.148/<.001 .123 (.19) .327 (<.001)
Age 0.99 (0.95-1.02) 0.46 0.98 (0.95-1.01) 0.98 .05 (.82) .10 (.39)
Female 1.54 (0.74-2.34) 0.29 3.08 (2.42-3.74) 0.001 .31 (.13) .34 (.005)
Black 1.15 (0.36-1.93) 0.73 0.68 (0.00-1.36) 0.27 .09 (.58) .44 (<.001)
Block 2:
socioeconomic
0.030/.71 0.151/.53 .037 (.48) .020 (.44)
Income 1.00 (0.98-1.01) 0.63 1.01 (0.99-1.02) 0.43 .141 (.44) .06 (.71)
Schooling 1.03 (0.91-1.15) 0.62 0.97 (0.87-1.07) 0.52 .18 (.31) .19 (.28)
Final model
Demographics
Age 0.99 (0.95-1.03) 0.61 0.99 (0.96-1.02) 0.56 .02 (.94) .10 (.41)
Female 0.93 (0.00-2.24) 0.92 2.05 (0.94-3.16) 0.21 .25 (.38) .44 (.02)
Black 1.08 (0.25-1.91) 0.86 0.80 (0.08-1.51) 0.53 .14 (.45) .45 (<.001)
Socioeconomic
Income 1.00 (0.98-1.01) 0.60 1.01 (0.99-1.02) 0.44 .13 (.49) .03 (.85)
Schooling 1.04 (0.84-1.24) 0.69 0.96 (0.87-1.06) 0.44 .20 (.30) .17 (.34)
Cancer and
treatment
0.062/.58 0.195/.22 .013 (.78) .013 (.58)
Prostate cancer 0.73 (0.00-2.14) 0.66 0.89 (0.00-2.06) 0.85 .11 (69) .18 (.32)
Chemotherapy 1.77 (0.85-2.69) 0.23 1.64 (0.80-2.44) 0.22 .07 (.73) .09 (.47)
Radiation therapy 1.53 (0.72-2.34) 0.30 1.55 (0.86-2.23) 0.22
Hormone therapy 0.72 (0.00-1.17) 0.58 1.63 (0.57-2.69) 0.37
Surgery 1.03 (0.10-1.97) 0.94 1.82 (0.80-4.43) 0.15
CI indicates confidence interval; BPI, Brief Pain Inventory.
aNagelkerke R2 is included, along with significance for added block. Because logistic regression does not require normal distribution, the Nagelkerke is only
an estimate.
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pain. Blacks were also more likely to be contacted to par-
ticipate than whites because we needed adequate numbers
for statistical analysis, thus each black had a higher proba-
bility of selection. Despite oversampling, noncoercive
monetary incentives to compensate subjects, and using
Dillman’s Total Design Method, blacks were less likely to
participate and more likely to have a bad address. This has
been observed in past studies, but may also be confounded
with poorer health, as blacks have earlier mortality and
lower survivorship rates for cancer.46,47 Future studies
should address whether these limitations are because of
recruitment challenges, geographic mobility, or a survival
effect. Regardless, we revealed important new findings
regarding differences and disparities in cancer-related CP,
while providing a sound platform for future studies focus-
ing on cancer survivorship in diverse samples.
In summary, we established the high prevalence
(nearly 20%) of cancer-related CP and its tremendous
impact on black and white cancer survivors. More than
40% of survivors experienced pain since their cancer diag-
nosis, with blacks and women more impacted than whites
and men. Considering the increasing prevalence of pain
and cancer and persistent health disparities in an increas-
ingly aging and diverse society, these results are particu-
larly salient. We provide new knowledge about cancer-
related CP and its impact on overall health and QOL. We
also identify important barriers, while presenting new
opportunities for research focusing on interventions (eg,
patient, clinician, health system, and health policy)
designed to improve health and pain care quality. We pro-
vide a sound platform for research focusing on survivor-
ship and cancer-related CP as well as for optimizing pain
care in diverse cancer survivors. All in all, the high preva-
lence of cancer and pain and now cancer-related CP
among diverse survivors (especially blacks and women)
reveals new opportunities for clinical care, research, and
policy.24
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